The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma

Trial Profile

The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 15 Feb 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
    • 20 May 2007 Results have been reported.
    • 24 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top